Paper · 41781908
Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1).
Nakamura Y and 19 others. BMC Cancer, 2026. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1). Papers, record 41781908. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41781908
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1).
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Immunological | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Nivolumab | Major topic |
| Skin Neoplasms | Major topic |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Non-Melanoma Skin Neoplasms | |
| Treatment Outcome |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1,607,418 | Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. | J Am Acad Dermatol | 1992 | https://conductscience.org/library/papers/1607418 | PubMed |
| 2 | 37,210,651 | Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies. | J Eur Acad Dermatol Venereol | 2023 | https://conductscience.org/library/papers/37210651 | PubMed |
| 3 | 29,442,540 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29442540 | PubMed |
| 4 | 20,566,926 | Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study. | Arch Dermatol | 2010 | https://conductscience.org/library/papers/20566926 | PubMed |
| 5 | 27,473,450 | Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: A retrospective cohort study. | J Am Acad Dermatol | 2016 | https://conductscience.org/library/papers/27473450 | PubMed |
| 6 | 34,000,246 | Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34000246 | PubMed |
| 7 | 30,395,155 | Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. | Ann Oncol | 2019 | https://conductscience.org/library/papers/30395155 | PubMed |
| 8 | 31,952,975 | Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/31952975 | PubMed |
| 9 | 25,891,173 | Pembrolizumab versus Ipilimumab in Advanced Melanoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25891173 | PubMed |
| 10 | 21,810,686 | Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21810686 | PubMed |
1 to 10 of 38
See all 38 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,720,694 | The mechanism of malignant progression in extramammary Paget's disease (EMPD): hallmarks of EMPD. | Med Mol Morphol | 2026 | https://conductscience.org/library/papers/42720694 | PubMed |
| 42,649,901 | Treatment Strategies for Extramammary Paget Disease: A Narrative Review of Current Status and Future Directions. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649901 | PubMed |
| 42,426,968 | Etoposide as Late-Line Therapy for Metastatic Extramammary Paget's Disease: A Case Series. | J Dermatol | 2026 | https://conductscience.org/library/papers/42426968 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41781908
GET https://conductscience.org/api/papers/v1/41781908/references?page=2